$54.90

4.77 (9.52%)

11/21/2008 4:00 PM

Amgen, Inc. (AMGN)

CAPS Rating:

A biotechnology company whcih discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating AMGN

Add Stock to Watchlist

What the Community Thinks

Total Members

1735 Outperforms

155 Underperforms

All-Stars

513 Outperforms

32 Underperforms

Wall Street

26 Outperforms

1 Underperforms

Members bullish on AMGN are also bullish on:

Members bearish on AMGN are also bearish on:

Ticker Tags

Serial Acquirer (9), Thousand Oaks (1), Business Week 50 (49), California (41), Biotechnology (230), Mega Cap (60), S&P 500 (469), Rule Breakers Universe (137), Dermatology (5), Nasdaq 100 (88)
Suggest a tag

Amgen, Inc. At A Glance

Current Price:	$54.90
Last Trade Time:	11/21/2008 4:00 PM
Open:	$51.55
Previous Close:	$50.13
Daily Range:	$51.10 - $55.08
52-Week Range:	$27.00 - $66.51
Volume:	19,368,807
Market Cap:	$53.11B
P/E Ratio:	13.30
Compare Our Special Broker Offers!

Stock Trends

AMGN VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for AMGN

Final Glance: Biotechnology companies
11/21/2008 6:14:00 PM - AP
Midday Glance: Biotechnology companies
11/21/2008 1:30:00 PM - AP
Amgen gets positive EU nod for blood-clot drug
11/21/2008 11:28:00 AM - AP
Early Glance: Biotechnology companies
11/21/2008 10:32:00 AM - AP

More Headlines...

Top Bull Pitch

Recs

1 Amgen, Inc. (AMGN)

Avatar jep2224 (< 20) Submitted: 3/24/08 2:04 PM

If and hopefully when cash dividends are announced to sooth long time investors, a whole new class of funds and investors will flock to this stock. the benefits will be tw fold: create demand and stabize the wild fluctuations in stock price

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1 Amgen, Inc. (AMGN)

Avatar not2eager (94.80) Submitted: 9/20/07 2:24 PM

Say goodbye to yesteryear. Management has engaged in almost every tactic to save the sinking ship: stock buybacks (which reenter the market as options), speculative takeovers to fill a weak pipeline, paying off doctors to over-prescribe lawyering the bad news ... every tactic but producing a foll...More

Replies: 0 | Reply | Permalink

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 316 : 1 2 3 4 5 Next » Jump to page:

Recs 0 (AMGN) WilliamCrook2007 (22.91) Submitted: 11/20/08 2:54 PM : Start Price: $52.41 AMGN Score: 8.99 ibd Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AMGN) craftmacaroni (62.66) Submitted: 11/14/08 12:43 PM : Start Price: $59.06 AMGN Score: 7.05 Nice steady earnings growth. Should perform even if we're in a recession for a while. Compelling valuations. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AMGN) ETFinnovators (88.44) Submitted: 11/12/08 6:47 PM : Start Price: $56.83 AMGN Score: 9.35 ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices? The accompanying table includes statistics and the top five rated companies in the ETFI Global Health Innovators Index of companies with market caps over $100M which received FDA approval in the trailing 12-month period for either an original new drug or medical device product. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies which receive original PMA approvals for new medical devices are included in the index, excluding the less rigorous and more numerous 510(k) applications. The goal of the index is to track the performance of companies which are developing innovative new drugs and medical devices to see whether their investment in R&D pays off in the form of better stock price performance compared to benchmark ETFs for pharma, biotech, medical devices, and the overall healthcare sector. The top 25 rated companies fared better than five of the six benchmark funds while all 49 companies fared better than three of the six. The top rated companies in the index reflect a mix of new product approvals, including Baxter (BAX) BioSurgery's skin graft adhesive for burn patients (Artiss), new medical devices from Abbott Labs (ABT) (Xience V stent) and Thoratec (THOR) (HeartMate), a cancer drug from Cephalon (CEPH) (Treanda), and a biological agent (Cinryze) from ViroPharma (VPHM) which was acquired with its buyout of Lev Pharma. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AMGN) scuba2007 (< 20) Submitted: 11/12/08 1:50 AM : Start Price: $57.52 AMGN Score: 9.48 we are at the beginning of a decade that will see tremendous growth in molecular and genetic medicine Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AMGN) MViscio1 (26.43) Submitted: 10/23/08 12:10 PM : Start Price: $55.64 AMGN Score: 14.42 BIO TECH Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 316 : 1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 27 of 27

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackLeerinkSwan	92.44	08/20/08		NS	$64.05	-14.29%	-40.47%	+26.18
	TrackBofASec	95.85	08/04/08		NS	$63.17	-13.09%	-39.86%	+26.76
	TrackOppenheimer	< 20	07/29/08		NS	$63.09	-12.98%	-38.86%	+25.88
	TrackCitigroup	< 20	07/29/08		NS	$63.09	-12.98%	-38.86%	+25.88
	TrackMorganJos	< 20	07/28/08		NS	$62.07	-11.55%	-39.58%	+28.03
	TrackJefferies	< 20	07/28/08		NS	$62.07	-11.55%	-39.58%	+28.03
	TrackRodmanRen	51.88	07/28/08		NS	$62.07	-11.55%	-39.58%	+28.03
	TrackDeutscheSec	< 20	06/19/08		NS	$44.41	+23.62%	-43.46%	+67.08
	TrackSnow	67.69	06/18/08		1Y	$44.62	+23.04%	-43.63%	+66.67
	TrackMuhlenkamp	< 20	06/12/08		1Y	$43.36	+26.61%	-43.74%	+70.36
	TrackSoros	< 20	03/31/08		NS	$41.78	+31.40%	-42.54%	+73.94
	TrackJimCramer	85.65	01/18/08		3W	$47.45	+15.70%	-42.63%	-58.33
	TrackDodgeCox	94.99	12/31/07		NS	$46.44	+18.22%	-48.13%	+66.35
	TrackLehmanBros	< 20	11/15/07		NS	$54.33	+1.05%	-48.26%	+49.31
	TrackCreditSuiss	< 20	10/24/07		NS	$57.80	-5.02%	-49.85%	+44.83
	TrackDreman	85.36	09/30/07		NS	$56.57	-2.95%	-50.30%	+47.35
	TrackBrandes	< 20	09/30/07		NS	$56.57	-2.95%	-50.30%	+47.35
	TrackNWQ	< 20	09/30/07		NS	$56.57	-2.95%	-50.30%	+47.35
	TrackRichPzena	21.48	09/30/07		NS	$56.57	-2.95%	-50.30%	+47.35
	TrackEdwardOwens	99.48	09/30/07		NS	$56.57	-2.95%	-50.30%	+47.35
	TrackHillman	72.20	09/30/07		NS	$56.57	-2.95%	-50.30%	+47.35
	TrackBRogers	96.96	09/30/07		NS	$56.57	-2.95%	-50.30%	+47.35
	TrackChrisDavis	< 20	09/30/07		NS	$56.57	-2.95%	-50.30%	+47.35
	TrackMichaelSivy	97.68	03/20/07		1Y	$55.85	-1.70%	-46.21%	+44.50
	TrackBearStearns	25.14	01/04/07		NS	$69.99	-21.56%	-46.00%	+24.44

Results 1 - 27 of 27

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.